These findings suggest that Flt3 may be a promising therapeutic target for cardiac remodeling and heart failure since protecting L-OPA1 from processing can efficiently reduce mitochondrial network fragmentation and apoptosis. The gene discussed is FLT3; the disease is heart failure.